Hormonal
The 'no-dipper' blood pressure pattern (lack of nocturnal BP reduction) is independently associated with higher cardiovascular risk and organ damage, regardless of standard Framingham risk scores or confirmed hypertension diagnosis.
If you have high blood pressure or cardiovascular risk, standard office checks might not tell the whole story. Ask your doctor about 24-hour ambulatory blood pressure monitoring (ABPM). This test checks if your blood pressure drops at night (dipping). If it doesn't (no-dipper), your risk of heart attack, stroke, and kidney damage is higher, even if your daytime readings look okay. Managing this pattern may require specific timing of medications (chronotherapy) or lifestyle changes to restore normal nighttime drops.
In the multivariate logistic regression model... age (OR= 1.06... ) and obesity (OR= 1.82...), but not the EFRCV, were independently associated with the ND condition... This finding suggests that the well-established relationship between the ND condition and cardiovascular events is explained by pathways different from those included in the EFRCV.
Why this rating
Based on a large cohort (CHICAMOCHA) with ambulatory monitoring, though the specific study is cross-sectional; supported by extensive literature cited.
Source
Risk Factors for Acute Myocardial Infarction in Latin America
Fernando Laņas et al. · Circulation · 2007
DOI 10.1161/circulationaha.106.633552
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →